← Back
$SYRE All transactions

Spyre Therapeutics, Inc.

A

$ Value

$0

Shares

25,000

Price

$0

Filed

Jun 2

Insider

Name

Fairmount Funds Management LLC

Title

CIK

0001802528

Roles

Director

Transaction Details

Transaction Date

2025-05-29

Code

A

Table

Derivative

Ownership

Indirect

Equity Swap

No

Shares After

25,000

Footnotes

This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Peter Harwin's continuous service with the Issuer at each vesting date. | Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein. | This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Tomas Kiselak's continuous service with the Issuer at each vesting date. | Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.

Filing Info

Accession No.

0001636282-25-000069

Form Type

4

Issuer CIK

0001636282

Fairmount Funds Management LLC's History

Date Ticker Type Value
2026-03-31 COGT C
2026-03-31 COGT $242.6M
2026-03-31 COGT C $0
2026-03-31 ZBIO $3.0M
2026-03-23 DMRA A $0
2025-10-23 VRDN $10.0M
2025-10-07 ZBIO $6.0M
2025-10-06 JBIO A $12.2M
2025-10-06 JBIO A $7.8M
2025-09-17 ORKA A $5.0M

Other Insiders at SYRE (90d)

Insider Bought Sold Last
Turtle Cameron
Chief Executive Officer
$740K 2026-04-01
Burrows Scott L
Chief Financial Officer
$370K 2026-04-01
Sloan Sheldon
Chief Medical Officer
$398K 2026-04-01